Results 141 to 150 of about 14,165 (152)

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

New England Journal of Medicine, 2018
Igor N Bondarenko, Seock-Ah Im, Norikazu Masuda   +2 more
exaly  

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

Drugs, 2020
C Louwrens Braal
exaly  

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma

Gut, 2017
Marina Ruiz de Galarreta, Daniela Sia, Shigeki Nakagawa   +2 more
exaly  

Palbociclib

Reactions Weekly, 2015
openaire   +1 more source

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

Lancet Oncology, The, 2018
Luca Gianni, Giancarlo Bisagni, Marco Colleoni   +2 more
exaly  

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

Nature Communications, 2018
Ben O'Leary, Yuan Liu, cynthia Huang Bartlett   +2 more
exaly  

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial

Lancet Oncology, The, 2019
Douglas R Adkins, Kevin Palka, Juneko E Grilley-Olson   +2 more
exaly  

The history and future of targeting cyclin-dependent kinases in cancer therapy

Nature Reviews Drug Discovery, 2015
Erik S Knudsen
exaly  

Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

Lancet Oncology, The, 2019
Yeon Hee Park, Tae-Yong Kim, Gun Min Kim
exaly  

Palbociclib

Reactions Weekly, 2016
openaire   +1 more source